Intermediate Results of Prospective Observational Study: The 2-year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice

Aim. To assess efficacy and toxicity of ibrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL). Materials & Methods. In this group of patients ibrutinib has been used since April 2016. Ibrutinib administration criteria were the age > 18 years and the confirmed MCL d...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Vladimir Ivanovich Vorob’ev, V. A. Zherebtsova, E. I. Dubrovin, L. A. Bychenkova, Yu. B. Kochkareva, L. A. Mukha, V. L. Ivanova, N. K. Khuazheva, V. V. Ptushkin
Formato:	Artigo
Idioma:	Russo
Publicado em:	Practical Medicine Publishing House 2019-04-01
coleção:	Клиническая онкогематология
Assuntos:	mantle cell lymphoma ibrutinib relapse refractory course targeted therapy
Acesso em linha:	https://bloodjournal.ru/index.php/coh/article/view/307
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!